Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Genome Engineering Global Market Report 2022: Increasing Funding and Investments for Research and Development Present Lucrative Opportunities
08 déc. 2022 06h08 HE
|
Research and Markets
Dublin, Dec. 08, 2022 (GLOBE NEWSWIRE) -- The "Genome Engineering Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Technology (CRISPR, TALEN, ZFN,...
Advanced Genomics Market Research Report 2022: Key Disruptive Forces to Transform Health and Wellness
23 nov. 2022 06h55 HE
|
Research and Markets
Dublin, Nov. 23, 2022 (GLOBE NEWSWIRE) -- The "Advanced Genomics - Key Disruptive Forces to Transform Health and Wellness" report has been added to ResearchAndMarkets.com's offering.Advances in...
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong...
CRISPR and CAS Genes Global Market to Expand by 26.82% Yearly Through 2029
07 nov. 2022 05h40 HE
|
Research and Markets
Dublin, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The "CRISPR and CAS Genes Market Analysis by Product & Service, by Application by End user, and by Region - Global Forecast to 2029" report has been...
CAS9 Technology Market To Reach USD 6.72 Billion at a CAGR of 11.30% by 2030 - Report by Market Research Future (MRFR)
03 nov. 2022 09h02 HE
|
Market Research Future
New York, US, Nov. 03, 2022 (GLOBE NEWSWIRE) -- According to a comprehensive research report by Market Research Future (MRFR), “CAS9 Technology Market: Product Type, Application, Delivery Method,...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
19 oct. 2022 09h00 HE
|
Telesis Bio
SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company,...
Global CRISPR Technology Intellectual Property Landscape Report 2022: Identify Key Trends that Describe the Pace and Focus of Innovation Related to CRISPR / CAS Technologies
18 oct. 2022 08h53 HE
|
Research and Markets
Dublin, Oct. 18, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Technologies: Intellectual Property Landscape(Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent...
Global Cell and Gene Therapy (CGT) Market Analysis Report 2022: Shift to Prevalent Diseases and Allogeneic Cell Therapies Creates New Growth Opportunities in the CGT Value Chain
07 oct. 2022 06h38 HE
|
Research and Markets
Dublin, Oct. 07, 2022 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy (CGT) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study examines the global...
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
16 sept. 2022 07h15 HE
|
Intellia Therapeutics, Inc.
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses,...